Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1537-2995.2003.00363.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A let-7 microRNA-RALB axis links the immune properties of iPSC-derived megakaryocytes with platelet producibility.
Nat Commun
March 2024
Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
We recently achieved the first-in-human transfusion of induced pluripotent stem cell-derived platelets (iPSC-PLTs) as an alternative to standard transfusions, which are dependent on donors and therefore variable in supply. However, heterogeneity characterized by thrombopoiesis-biased or immune-biased megakaryocytes (MKs) continues to pose a bottleneck against the standardization of iPSC-PLT manufacturing. To address this problem, here we employ microRNA (miRNA) switch biotechnology to distinguish subpopulations of imMKCLs, the MK cell lines producing iPSC-PLTs.
View Article and Find Full Text PDFPredominant control of PDGF/PDGF receptor signaling in the migration and proliferation of human adipose‑derived stem cells under culture conditions with a combination of growth factors.
Exp Ther Med
April 2024
Department of Plastic and Reconstructive Surgery, Kansai Medical University, Hirakata, Osaka 573-1010, Japan.
Human adipose-derived stem cells (hASCs) play important roles in regenerative medicine and tissue engineering. However, their clinical applications are limited because of their instability during cell culture. Platelet lysates (PLTs) contain large amounts of growth factors that are useful for manufacturing cellular products.
View Article and Find Full Text PDFMass production of iPSC-derived platelets toward the clinical application.
Regen Ther
March 2024
Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Shōgoin Kawarachō, Sakyo Ward, Kyoto, 606-8397, Japan.
The production of platelets from induced pluripotent cells (iPSCs) may offer a safer and sustainable alternative for transfusions and drug delivery systems (DDS). However, the mass production of the clinically required number of iPSC-derived platelets (iPSC-PLTs) is challenging. Here, we introduce recent technologies for mass production and the first-in-human clinical trial using iPSC-PLTs.
View Article and Find Full Text PDFPlatelet extracellular vesicles are efficient delivery vehicles of doxorubicin, an anti-cancer drug: preparation and in vitro characterization.
Platelets
December 2023
Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei, Taiwan.
Platelet extracellular vesicles (PEVs) are an emerging delivery vehi for anticancer drugs due to their ability to target and remain in the tumor microenvironment. However, there is still a lack of understanding regarding yields, safety, drug loading efficiencies, and efficacy of PEVs. In this study, various methods were compared to generate PEVs from clinical-grade platelets, and their properties were examined as vehicles for doxorubicin (DOX).
View Article and Find Full Text PDFEx vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets.
Int J Hematol
March 2023
Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
Platelet transfusion is a common clinical approach to providing platelets to patients suffering from thrombocytopenia or other ailments that require an additional platelet source. However, a stable supply of platelet products is challenged by aging societies, pandemics, and other factors. Many groups have made extensive efforts toward the in vitro generation of platelets for clinical application.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!